Targeting Fibrosis by inhibiting Chemotaxis
A new revolution in asthma care is on its way. Fibraxis are developing a first-in-class inhalable daily medication that halts and reverses the structural lung damage that occurs in asthma.
Revolutionising Asthma Care for a Healthier Tomorrow
Our innovative inhaled medication not only alleviates symptoms but also addresses the underlying causes of asthma. Experience a new era of asthma management that prioritises long-term health.
Comprehensive Relief
Targeting root causes leads to lasting improvements in lung function and overall well-being.
Enhanced Quality
Our solution integrates seamlessly into daily routines, making asthma management easier than ever.
Challenge
Asthma is more than inflammation
Technological innovation
A first-in-class therapeutic breakthrough
Our unique approach blocks pericyte chemotaxis, directly targeting the root cause of airway remodelling. This breakthrough promises to improve breathing mechanics at a fundamental level.
Turning scientific discovery into real-world therapies
About Fibraxis
Fibraxis is a spin-out from Aston University, born from decades of lung research and a passion for transforming asthma care.
Our team of scientists and innovators has uncovered a novel pathway that drives structural lung damage, leading to the development of a first-in-class therapeutic.
Together, we are translating cutting-edge discovery into a therapy with the potential to redefine how asthma is treated.
Latest News
Transforming Asthma Treatment Through Science
Our Partners
